- Home
- CRMD vs BME Comparison
CRMD vs BME Comparison
Compare CRMD & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRMD | BME |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.8M | 547.5M |
| IPO Year | 2009 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CRMD | BME |
|---|---|---|
| Price | $6.93 | $42.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $15.29 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 34.4K |
| Earning Date | 04-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.03 | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $43,472,170.00 | N/A |
| Revenue This Year | $627.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.51 | ★ N/A |
| Revenue Growth | ★ 66363.08 | N/A |
| 52 Week Low | $5.60 | $34.18 |
| 52 Week High | $17.43 | $42.74 |
Technical Indicators
Market Signals| Indicator | CRMD | BME |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 52.92 |
| Support Level | $6.55 | $41.41 |
| Resistance Level | $8.53 | $42.46 |
| Average True Range (ATR) | 0.28 | 0.52 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 12.17 | 53.98 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.